Norden Gregory 4

What Happened
Gregory Norden, a director of Royalty Pharma plc (RPRX), was granted an award of 4,545 restricted stock units (RSUs) on 2026-06-05. The grant price reported is $0.00, so there was no cash transfer at the time of the grant. This is an equity award (routine director compensation) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; filing date (Form 4): 2026-06-08.
• Transaction type/code: A — Award/Grant of RSUs. Reported price: $0.00; reported value: $0 at grant.
• Shares granted: 4,545 restricted stock units.
• Shares owned following the transaction: not disclosed in the provided excerpt.
• Footnote: The RSUs are granted under the 2020 Independent Director Equity Incentive Plan and are generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant or (ii) the date of the annual meeting in the first calendar year after the grant, subject to the plan and award agreement.
• No indication in the excerpt of tax withholding, a 10b5-1 plan, or a cashless exercise—this is a standard restricted stock unit grant.

Context
RSU grants to directors are common as part of compensation and do not involve immediate cash flow. Because the units vest in the future (per the footnote), they do not represent freely tradeable shares today. Awards like this are informative about compensation practices but are not the same signaling event as an insider purchase or sale of already vested shares.